Pub Date : 2025-08-01Epub Date: 2025-06-02DOI: 10.1016/j.hermed.2025.101034
Mengli Xiao , Liying Zhang , Beihua Zhang , Liqun Bian , Zhenhua Li , Junxiang Li , Wei Wei , Min Liu , Li Liu , Chuijie Wang , Shaohong Shi , Jinkang Xu , Sheng Xie , Hong Shen , Qiang Yang , Guangjun Yan , Mingqi Wen , Fang Lu , Xudong Tang
Introduction
Traditional Chinese Medicine (TCM) has been found to be effective in the treatment of Helicobacter pylori (H. pylori). However, the quality of evidence is limited and there are few studies on TCM of H. pylori. This trials aimed to examine whether additional use of TCM can lead to better efficacy in the eradication rate of H. pylori.
Methods
This study consisted of a multicenter randomized controlled trial and a nonrandomized cohort. Subjects from TCM hospitals were allocated to a treatment group that received triple therapy or a combination group that received triple therapy combined with 2 weeks of herbal bulk or 2 weeks of herbal soup or 4 weeks of herbal soup. Patients in western hospitals received triple therapy (non-randomized control group). The eradication rate of H. pylori, the recurrence rate, the TCM symptom score, the patient-reported outcome scale (PRO), and safety indicators were observed and compared.
Results
960 patients screened, 768 were randomly assigned to the randomized treatment group, and 192 were assigned to the non-randomized group. No difference in the H. pylori eradication rate between the combination group compared with triple therapy (P > 0.05). Significant improvements were observed in TCM symptom scores, the quality of life in the combination group (P < 0.05). Moreover, it had a lower incidence of adverse reactions and rates of H. pylori recurrence (P < 0.05).
Conclusion
The additional use of TCM in triple therapy improves the quality of life, reduces adverse effects, and recurrence rates.
{"title":"Comparative evaluation of the clinical efficacy of triple therapy and the addition use of TCM in treating Helicobacter pylori-associated gastritis","authors":"Mengli Xiao , Liying Zhang , Beihua Zhang , Liqun Bian , Zhenhua Li , Junxiang Li , Wei Wei , Min Liu , Li Liu , Chuijie Wang , Shaohong Shi , Jinkang Xu , Sheng Xie , Hong Shen , Qiang Yang , Guangjun Yan , Mingqi Wen , Fang Lu , Xudong Tang","doi":"10.1016/j.hermed.2025.101034","DOIUrl":"10.1016/j.hermed.2025.101034","url":null,"abstract":"<div><h3>Introduction</h3><div>Traditional Chinese Medicine (TCM) has been found to be effective in the treatment of Helicobacter pylori (<em>H. pylori</em>). However, the quality of evidence is limited and there are few studies on TCM of <em>H. pylor</em>i. This trials aimed to examine whether additional use of TCM can lead to better efficacy in the eradication rate of <em>H. pylori</em>.</div></div><div><h3>Methods</h3><div>This study consisted of a multicenter randomized controlled trial and a nonrandomized cohort. Subjects from TCM hospitals were allocated to a treatment group that received triple therapy or a combination group that received triple therapy combined with 2 weeks of herbal bulk or 2 weeks of herbal soup or 4 weeks of herbal soup. Patients in western hospitals received triple therapy (non-randomized control group). The eradication rate of <em>H. pylori</em>, the recurrence rate, the TCM symptom score, the patient-reported outcome scale (PRO), and safety indicators were observed and compared.</div></div><div><h3>Results</h3><div>960 patients screened, 768 were randomly assigned to the randomized treatment group, and 192 were assigned to the non-randomized group. No difference in the <em>H. pylori</em> eradication rate between the combination group compared with triple therapy (<em>P ></em> 0.05). Significant improvements were observed in TCM symptom scores, the quality of life in the combination group (<em>P</em> < 0.05). Moreover, it had a lower incidence of adverse reactions and rates of <em>H. pylori</em> recurrence (<em>P</em> < 0.05).</div></div><div><h3>Conclusion</h3><div>The additional use of TCM in triple therapy improves the quality of life, reduces adverse effects, and recurrence rates.</div></div>","PeriodicalId":56077,"journal":{"name":"Journal of Herbal Medicine","volume":"52 ","pages":"Article 101034"},"PeriodicalIF":2.2,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144687070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-01Epub Date: 2025-05-16DOI: 10.1016/j.hermed.2025.101029
Asma Irfan , Saleeha Fatima Said , Soma Siddique , Muhammad Hassaan Farooq , Noor ul Ain Irfan , Sadia Mubarak , Saima Latif , Rubab Rameez , Saira Safdar , Irfan A. Mughal , Areej Niazi , Yasir Khan Niazi , Syed Haider Raza Rizvi , Aleena Naveed Butt , Khawaja Muhammad Usman , Muhammad Azadar Abbas , Muhammad Ibrahim Khan , Shaheer Zaman
Introduction
Moringa oleifera leaves have demonstrated hypoglycemic effects in diabetic patients. However, there is limited clinical evidence supporting their use as an adjunct therapy alongside standard antidiabetic treatment. This study evaluates the synergistic effects of M. oleifera leaf methanolic extracts in combination with Metformin on glycemic control in type 2 diabetes mellitus (T2DM) patients.
Methods
A randomised controlled trial was conducted at Akbar Niazi Teaching Hospital (ANTH), Islamabad, from February 2023 to November 2023. A total of 50 participants (25 control, 25 case) were recruited using the World Health Organization sample size calculator. Patients diagnosed with T2DM, on Metformin 500 mg twice daily, and willing to participate were included. Informed consent was obtained, and triple blinding was maintained. The case group received Metformin plus Moringa leaf capsules containing 1 g of Moringa powder, while the control group received Metformin and a placebo. Fasting blood glucose, HbA1c, liver function tests (LFTs), renal function tests (RFTs), and lipid profiles were monitored. The study was registered at http://clinicaltrials.gov (NCT06125873) and approved by the Institutional Review Board of Islamabad Medical and Dental College.
SPSS version 26 was used for statistical analysis. Continuous variables were expressed as mean ± SD or median (min, max), while categorical variables were presented as frequencies and percentages. Paired t-tests and two-way Analysis of Variance were performed to assess pre- and post-treatment effects, with significance set at P < 0.05.
Results
Participants receiving M. oleifera demonstrated significant improvements in HbA1c levels, fasting blood glucose, and blood pressure compared to the placebo group. However, no significant changes were observed in body mass index (BMI), LFTs, RFTs, or lipid profiles. Some individuals reported mild gastric discomfort, which resolved with dosage adjustment in the 1st week.
Conclusion
This study suggests that M. oleifera, when used as an adjunct to Metformin, significantly improves glycemic control in T2DM patients. The absence of significant changes in BMI, LFTs, RFTs, and lipid profiles indicates its safety for human use.
辣木叶对糖尿病患者有降糖作用。然而,有限的临床证据支持它们作为标准抗糖尿病治疗的辅助治疗。本研究评价油松叶甲醇提取物联合二甲双胍对2型糖尿病(T2DM)患者血糖控制的协同作用。方法于2023年2月至11月在伊斯兰堡Akbar Niazi教学医院(ANTH)进行随机对照试验。使用世界卫生组织样本量计算器共招募了50名参与者(25名对照,25名病例)。被诊断为T2DM的患者,每天两次服用二甲双胍500 mg,并愿意参与研究。获得知情同意,并保持三重盲法。病例组服用二甲双胍加含有1 g辣木粉的辣木叶胶囊,对照组服用二甲双胍加安慰剂。监测空腹血糖、HbA1c、肝功能检查(LFTs)、肾功能检查(RFTs)和血脂。该研究已在http://clinicaltrials.gov (NCT06125873)上注册,并得到伊斯兰堡医学和牙科学院机构审查委员会的批准。采用SPSS version 26进行统计分析。连续变量用均值±SD或中位数(min, max)表示,分类变量用频率和百分比表示。采用配对t检验和双向方差分析来评估治疗前后的效果,显著性设置为P <;0.05.结果:与安慰剂组相比,接受油酸支原体治疗的患者在HbA1c水平、空腹血糖和血压方面均有显著改善。然而,在体重指数(BMI)、LFTs、RFTs或脂质谱方面没有观察到显著变化。一些人报告轻微的胃部不适,在第一周调整剂量后缓解。结论本研究提示,油葵作为二甲双胍的辅助用药,可显著改善T2DM患者的血糖控制。BMI、LFTs、RFTs和脂质谱无显著变化,表明其对人类使用是安全的。
{"title":"Synergistic effects of Moringa oleifera with metformin in improving glycemic control in type 2 diabetics through a randomised controlled trial","authors":"Asma Irfan , Saleeha Fatima Said , Soma Siddique , Muhammad Hassaan Farooq , Noor ul Ain Irfan , Sadia Mubarak , Saima Latif , Rubab Rameez , Saira Safdar , Irfan A. Mughal , Areej Niazi , Yasir Khan Niazi , Syed Haider Raza Rizvi , Aleena Naveed Butt , Khawaja Muhammad Usman , Muhammad Azadar Abbas , Muhammad Ibrahim Khan , Shaheer Zaman","doi":"10.1016/j.hermed.2025.101029","DOIUrl":"10.1016/j.hermed.2025.101029","url":null,"abstract":"<div><h3>Introduction</h3><div><em>Moringa oleifera</em> leaves have demonstrated hypoglycemic effects in diabetic patients. However, there is limited clinical evidence supporting their use as an adjunct therapy alongside standard antidiabetic treatment. This study evaluates the synergistic effects of <em>M. oleifera</em> leaf methanolic extracts in combination with Metformin on glycemic control in type 2 diabetes mellitus (T2DM) patients.</div></div><div><h3>Methods</h3><div>A randomised controlled trial was conducted at Akbar Niazi Teaching Hospital (ANTH), Islamabad, from February 2023 to November 2023. A total of 50 participants (25 control, 25 case) were recruited using the World Health Organization sample size calculator. Patients diagnosed with T2DM, on Metformin 500 mg twice daily, and willing to participate were included. Informed consent was obtained, and triple blinding was maintained. The case group received Metformin plus Moringa leaf capsules containing 1 g of Moringa powder, while the control group received Metformin and a placebo. Fasting blood glucose, HbA1c, liver function tests (LFTs), renal function tests (RFTs), and lipid profiles were monitored. The study was registered at <span><span>http://clinicaltrials.gov</span><svg><path></path></svg></span> (NCT06125873) and approved by the Institutional Review Board of Islamabad Medical and Dental College.</div><div>SPSS version 26 was used for statistical analysis. Continuous variables were expressed as mean ± SD or median (min, max), while categorical variables were presented as frequencies and percentages. Paired <em>t</em>-tests and two-way Analysis of Variance were performed to assess pre- and post-treatment effects, with significance set at <em>P</em> < 0.05.</div></div><div><h3>Results</h3><div>Participants receiving <em>M. oleifera</em> demonstrated significant improvements in HbA1c levels, fasting blood glucose, and blood pressure compared to the placebo group. However, no significant changes were observed in body mass index (BMI), LFTs, RFTs, or lipid profiles. Some individuals reported mild gastric discomfort, which resolved with dosage adjustment in the 1st week.</div></div><div><h3>Conclusion</h3><div>This study suggests that <em>M. oleifera</em>, when used as an adjunct to Metformin, significantly improves glycemic control in T2DM patients. The absence of significant changes in BMI, LFTs, RFTs, and lipid profiles indicates its safety for human use.</div></div>","PeriodicalId":56077,"journal":{"name":"Journal of Herbal Medicine","volume":"52 ","pages":"Article 101029"},"PeriodicalIF":2.2,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144213269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-01Epub Date: 2025-03-25DOI: 10.1016/j.hermed.2025.101012
Jennifer Cruz , Yan Zhao , Yuanhua Wang , Guiqing Ding , Jinyun Ma , Xiaohan Wang , Linda Carrington , Harry Hong , Di Fu , Xiaodong Cheng
Introduction
The coronavirus disease 2019 (COVID-19) pandemic has brought attention to long-COVID, characterised by persistent symptoms such as fatigue, neurological problems, and musculoskeletal pain, posing a significant health challenge worldwide.
Methods
This study utilised both a meta-analysis and retrospective study methods to explore novel post-COVID treatment options, including assessing Traditional Chinese Medicine (TCM) efficacy against COVID-19 and investigating effective TCM prescriptions for long-COVID symptoms. Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a comprehensive database search identified randomised controlled trials (RCTs) evaluating TCM's impact on COVID-19. Statistical software synthesised RCT data, calculating effect sizes, risk ratios (RR), and mean differences (MD) with 95% confidence intervals (CI). The retrospective study examined clinical records of long-COVID patients treated with Qū Dú Qiáng Fèi Yī Hào Fāng Mod. 3 (QDQF1 Mod. 3), applying strict eligibility criteria and a Subjective Symptom Survey Questionnaire (SSSQ) over 5 weeks.
Results
The study demonstrated TCM's effectiveness in enhancing overall COVID-19 treatment rates and reducing neurological symptoms such as fatigue and muscle pain. QDQF1 Mod. 3 significantly alleviated long-COVID symptoms with an 85% reduction in fatigue and notable muscle pain relief, all statistically significant (P < 0.01).
Conclusion
TCM, particularly QDQF1 Mod. 3, emerges as a promising adjunctive therapy for managing both COVID-19 and long-COVID symptoms, supported by combined meta-analysis and retrospective study findings.
Data and model availability statement
Data will be made available on request.
2019年冠状病毒病(COVID-19)大流行引起了人们对长期covid的关注,其特征是持续出现疲劳、神经问题和肌肉骨骼疼痛等症状,在全球范围内构成了重大的健康挑战。方法采用荟萃分析和回顾性研究相结合的方法,探索新型COVID-19后治疗方案,包括评估中医药治疗COVID-19的疗效,以及研究治疗COVID-19长期症状的有效中药处方。根据系统评价和荟萃分析(PRISMA)指南的首选报告项目,综合数据库检索确定了评估中医药对COVID-19影响的随机对照试验(rct)。统计软件综合RCT数据,以95%置信区间(CI)计算效应大小、风险比(RR)和平均差异(MD)。回顾性研究采用严格的入选标准和5周主观症状调查问卷(SSSQ),对QDQF1 Dú Qiáng f y ā Hào Fāng Mod. 3 (QDQF1 Mod. 3)治疗的长期covid患者的临床记录进行分析。结果中医药在提高COVID-19整体治愈率、减轻疲劳和肌肉疼痛等神经系统症状方面具有有效性。QDQF1 Mod. 3显着缓解了长时间covid症状,疲劳减轻85%,肌肉疼痛明显缓解,均具有统计学意义(P <;0.01)。结论综合meta分析和回顾性研究结果支持中医药,特别是QDQF1 Mod 3,是一种很有前景的治疗COVID-19和长期COVID-19症状的辅助疗法。数据和模型可用性声明数据将根据要求提供。
{"title":"Evaluating the efficacy of traditional Chinese medicine in treating COVID-19 and long-COVID symptoms: a combined meta-analysis and retrospective study","authors":"Jennifer Cruz , Yan Zhao , Yuanhua Wang , Guiqing Ding , Jinyun Ma , Xiaohan Wang , Linda Carrington , Harry Hong , Di Fu , Xiaodong Cheng","doi":"10.1016/j.hermed.2025.101012","DOIUrl":"10.1016/j.hermed.2025.101012","url":null,"abstract":"<div><h3>Introduction</h3><div>The coronavirus disease 2019 (COVID-19) pandemic has brought attention to long-COVID, characterised by persistent symptoms such as fatigue, neurological problems, and musculoskeletal pain, posing a significant health challenge worldwide.</div></div><div><h3>Methods</h3><div>This study utilised both a meta-analysis and retrospective study methods to explore novel post-COVID treatment options, including assessing Traditional Chinese Medicine (TCM) efficacy against COVID-19 and investigating effective TCM prescriptions for long-COVID symptoms. Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a comprehensive database search identified randomised controlled trials (RCTs) evaluating TCM's impact on COVID-19. Statistical software synthesised RCT data, calculating effect sizes, risk ratios (RR), and mean differences (MD) with 95% confidence intervals (CI). The retrospective study examined clinical records of long-COVID patients treated with Qū Dú Qiáng Fèi Yī Hào Fāng Mod. 3 (QDQF1 Mod. 3), applying strict eligibility criteria and a Subjective Symptom Survey Questionnaire (SSSQ) over 5 weeks.</div></div><div><h3>Results</h3><div>The study demonstrated TCM's effectiveness in enhancing overall COVID-19 treatment rates and reducing neurological symptoms such as fatigue and muscle pain. QDQF1 Mod. 3 significantly alleviated long-COVID symptoms with an 85% reduction in fatigue and notable muscle pain relief, all statistically significant (<em>P</em> < 0.01).</div></div><div><h3>Conclusion</h3><div>TCM, particularly QDQF1 Mod. 3, emerges as a promising adjunctive therapy for managing both COVID-19 and long-COVID symptoms, supported by combined meta-analysis and retrospective study findings.</div></div><div><h3>Data and model availability statement</h3><div>Data will be made available on request.</div></div>","PeriodicalId":56077,"journal":{"name":"Journal of Herbal Medicine","volume":"52 ","pages":"Article 101012"},"PeriodicalIF":2.2,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144330558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
This study assesses the efficacy of Squirrel Tail cannabis (CLE) in inhibiting cholangiocarcinoma cells (CCA; KKU213B).
Methods
The total phenolic content was quantified using the Folin-Ciocalteu reagent method. The study also sought to compare the efficacy of Squirrel Tail cannabis with gallic acid and evaluate the total flavonoid content using the AlCl3 colorimetric method, compared with the total flavonoid content of CLE with quercetin. Antioxidant activity was assessed through DPPH and ABTS assays. Key compounds in CLE were identified using High-performance liquid chromatography. Inhibition of cholangiocarcinoma cell growth was evaluated using the sulforhodamine B assay, and the mechanism of apoptosis was examined by analysing the expression of apoptosis-related proteins.
Results
The study found that the total phenolic content of CLE correlated with antioxidant activities. High-performance liquid chromatography analysis revealed that CLE contained 89.57 ± 10.34 µg/mg of cannabinol. Growth inhibition assays on KKU-213B cells indicated that cannabinol effectively inhibited cell growth, with IC50 values of 8.14 ± 0.10, 7.30 ± 0.38, and 4.00 ± 0.96 µM (24, 48, and 72 hours). CLE demonstrated the ability to inhibit KKU-213B cell growth with IC50 values of 55.26 ± 1.64, 42.25 ± 5.56, and 18.02 ± 9.43 µg/ml at 24, 48, and 72 hours, respectively, which were significantly different from those of the control group. Regarding the mechanism of apoptosis, CLE was found to stimulate the expression of p53, caspase-3, and Bax while reducing the expression of Bcl-2.
Conclusions
CLE from Sakon Nakhon strains may serve as a potential alternative for anticancer therapies.
{"title":"Impact of Cannabis Leaf (Sakon Nakhon Cultivar) Extracts on Anticholangiocarcinoma Activity","authors":"Pranee Sriraj , Thidarut Boonmars , Areeya Changthong , Praphat Manuelo Ruengthanoo , Panicha Pongnaratorn , Ratchadawan Aukkanimart","doi":"10.1016/j.hermed.2025.101028","DOIUrl":"10.1016/j.hermed.2025.101028","url":null,"abstract":"<div><h3>Introduction</h3><div>This study assesses the efficacy of Squirrel Tail cannabis (CLE) in inhibiting cholangiocarcinoma cells (CCA; KKU213B).</div></div><div><h3>Methods</h3><div>The total phenolic content was quantified using the Folin-Ciocalteu reagent method. The study also sought to compare the efficacy of Squirrel Tail cannabis with gallic acid and evaluate the total flavonoid content using the AlCl<sub>3</sub> colorimetric method, compared with the total flavonoid content of CLE with quercetin. Antioxidant activity was assessed through DPPH and ABTS assays. Key compounds in CLE were identified using High-performance liquid chromatography. Inhibition of cholangiocarcinoma cell growth was evaluated using the sulforhodamine B assay, and the mechanism of apoptosis was examined by analysing the expression of apoptosis-related proteins.</div></div><div><h3>Results</h3><div>The study found that the total phenolic content of CLE correlated with antioxidant activities. High-performance liquid chromatography analysis revealed that CLE contained 89.57 ± 10.34 µg/mg of cannabinol. Growth inhibition assays on KKU-213B cells indicated that cannabinol effectively inhibited cell growth, with IC<sub>50</sub> values of 8.14 ± 0.10, 7.30 ± 0.38, and 4.00 ± 0.96 µM (24, 48, and 72 hours). CLE demonstrated the ability to inhibit KKU-213B cell growth with IC<sub>50</sub> values of 55.26 ± 1.64, 42.25 ± 5.56, and 18.02 ± 9.43 µg/ml at 24, 48, and 72 hours, respectively, which were significantly different from those of the control group. Regarding the mechanism of apoptosis, CLE was found to stimulate the expression of p53, caspase-3, and Bax while reducing the expression of Bcl-2.</div></div><div><h3>Conclusions</h3><div>CLE from Sakon Nakhon strains may serve as a potential alternative for anticancer therapies.</div></div>","PeriodicalId":56077,"journal":{"name":"Journal of Herbal Medicine","volume":"52 ","pages":"Article 101028"},"PeriodicalIF":2.2,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144243450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-01Epub Date: 2025-05-22DOI: 10.1016/j.hermed.2025.101030
Chang Guan , Jian Wang , Peng Xu
Introduction
Myasthenia gravis is an autoimmune disease that primarily affects the acetylcholine receptors on the postsynaptic membrane at the neuromuscular junction. Traditional Chinese medicine (TCM) TSQNM formulas have been widely utilized in clinical practice and have shown effectiveness in treating Myasthenia gravis. There is a broad spectrum of TCM formulas with varying effectiveness, but there is a lack of direct comparative evidence between them. Bayesian network meta-analysis was utilized to evaluate the clinical efficacy and safety of TCM formulations that focus on spleen tonification, qi enhancement, and marrow nourishment (referred to as TSQNM) for treating myasthenia gravis. The results are anticipated to provide valuable insights into the treatment of myasthenia gravis.
Methods
Pertinent randomized controlled trials were retrieved from databases from the inception of the databases to October 17, 2023. The quality of studies was assessed using the risk of bias assessment tool developed by the Cochrane Collaboration. It was also preregistered in PROSPERO (ID: CRD42023482260). Network meta-analysis was conducted using STATA16 and R4.2.3.
Results
Twenty studies were included, involving 1 473 participants, with 739 cases in the experimental group and 734 cases in the control group. These studies examined the effectiveness of eight TCM formulas.
Conclusions
Combining conventional Western medicine treatment with TSQNM formulas has been shown to provide superior therapeutic effects for patients with myasthenia gravis, compared to using prescription drugs alone. Notably, when Buzhong Yiqi Decoction is combined with conventional Western medicine treatment, it has shown remarkable efficacy in reducing hormone-induced obesity and gastrointestinal tract discomfort.
{"title":"TCM formulas for strengthening the spleen, tonifying Qi, and supplementing the marrow in the treatment of MG: A network meta-analysis","authors":"Chang Guan , Jian Wang , Peng Xu","doi":"10.1016/j.hermed.2025.101030","DOIUrl":"10.1016/j.hermed.2025.101030","url":null,"abstract":"<div><h3>Introduction</h3><div>Myasthenia gravis is an autoimmune disease that primarily affects the acetylcholine receptors on the postsynaptic membrane at the neuromuscular junction. Traditional Chinese medicine (<strong>TCM</strong>) TSQNM formulas have been widely utilized in clinical practice and have shown effectiveness in treating Myasthenia gravis. There is a broad spectrum of TCM formulas with varying effectiveness, but there is a lack of direct comparative evidence between them. Bayesian network meta-analysis was utilized to evaluate the clinical efficacy and safety of TCM formulations that focus on spleen tonification, qi enhancement, and marrow nourishment (referred to as TSQNM) for treating myasthenia gravis. The results are anticipated to provide valuable insights into the treatment of myasthenia gravis.</div></div><div><h3>Methods</h3><div>Pertinent randomized controlled trials were retrieved from databases from the inception of the databases to October 17, 2023. The quality of studies was assessed using the risk of bias assessment tool developed by the Cochrane Collaboration. It was also preregistered in PROSPERO (ID: CRD42023482260). Network meta-analysis was conducted using STATA16 and R4.2.3.</div></div><div><h3>Results</h3><div>Twenty studies were included, involving 1 473 participants, with 739 cases in the experimental group and 734 cases in the control group. These studies examined the effectiveness of eight TCM formulas.</div></div><div><h3>Conclusions</h3><div>Combining conventional Western medicine treatment with TSQNM formulas has been shown to provide superior therapeutic effects for patients with myasthenia gravis, compared to using prescription drugs alone. Notably, when Buzhong Yiqi Decoction is combined with conventional Western medicine treatment, it has shown remarkable efficacy in reducing hormone-induced obesity and gastrointestinal tract discomfort.</div></div>","PeriodicalId":56077,"journal":{"name":"Journal of Herbal Medicine","volume":"52 ","pages":"Article 101030"},"PeriodicalIF":2.2,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144261377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Inflammation is a protective physiological response, but its chronic manifestation leads to adverse health outcomes. Current anti-inflammatory treatments often have significant side effects, necessitating safer alternatives. Mitragyna parvifolia, a medicinal plant, has demonstrated anti-inflammatory potential, though its mechanisms remain underexplored. The current study was designed to explore the anti-inflammatory mechanisms of M parvifolia, emphasising its potential as therapeutic agent for inflammatory diseases.
Methods
This study employed in silico approaches, including network pharmacology, molecular docking, and molecular dynamic simulations, to identify interactions between M parvifolia phytocompounds and inflammatory targets. Experimental validation was conducted using supercritical CO2 leaf extract, evaluated for cytotoxicity, protein denaturation, COX-2 inhibition, and HRBC membrane stabilisation and phytochemical profiling using LC-QTOF-MS analysis.
Results
Thirteen phytocompounds of M parvifolia were found to modulate 97 inflammatory targets, significantly impacting Interleukin-17 and TNF signalling pathways. Molecular docking revealed strong binding of compounds to key targets, including MMP9 and PTGS2, with the MMP9-Corynan-17-ol complex showing the highest stability in simulations. LC-QTOF-MS analysis identified 10 major bioactive constituents, supporting in silico predictions. Experimental assays confirmed low cytotoxicity (>90% cell viability) and demonstrated potent anti-inflammatory effects: 73.71% ± 1.5% inhibition of COX-2 activity, 73.9% ± 0.4% inhibition of protein denaturation, and 75.5% ± 0.83% HRBC membrane stabilisation at maximum concentrations.
Conclusions
M parvifolia exhibits significant anti-inflammatory properties through modulation of key pathways and targets, combined with strong experimental validation of its efficacy and safety. These findings position M parvifolia as a promising candidate for developing natural, safer anti-inflammatory therapies.
{"title":"Unravelling the Anti-inflammatory Potential of Mitragyna parvifolia: A Mechanistic and Data-Driven Approach to Herbal Medicine","authors":"Sukanya Pote , Preeti Salve , Sachin Gudasi , Shailendra Gurav","doi":"10.1016/j.hermed.2025.101038","DOIUrl":"10.1016/j.hermed.2025.101038","url":null,"abstract":"<div><h3>Introduction</h3><div>Inflammation is a protective physiological response, but its chronic manifestation leads to adverse health outcomes. Current anti-inflammatory treatments often have significant side effects, necessitating safer alternatives. <em>Mitragyna parvifolia</em>, a medicinal plant, has demonstrated anti-inflammatory potential, though its mechanisms remain underexplored. The current study was designed to explore the anti-inflammatory mechanisms of <em>M parvifolia</em>, emphasising its potential as therapeutic agent for inflammatory diseases.</div></div><div><h3>Methods</h3><div>This study employed <em>in silico</em> approaches, including network pharmacology, molecular docking, and molecular dynamic simulations, to identify interactions between <em>M parvifolia</em> phytocompounds and inflammatory targets. Experimental validation was conducted using supercritical CO<sub>2</sub> leaf extract, evaluated for cytotoxicity, protein denaturation, COX-2 inhibition, and HRBC membrane stabilisation and phytochemical profiling using LC-QTOF-MS analysis.</div></div><div><h3>Results</h3><div>Thirteen phytocompounds of <em>M parvifolia</em> were found to modulate 97 inflammatory targets, significantly impacting Interleukin-17 and TNF signalling pathways. Molecular docking revealed strong binding of compounds to key targets, including MMP9 and PTGS2, with the MMP9-Corynan-17-ol complex showing the highest stability in simulations. LC-QTOF-MS analysis identified 10 major bioactive constituents, supporting <em>in silico</em> predictions. Experimental assays confirmed low cytotoxicity (>90% cell viability) and demonstrated potent anti-inflammatory effects: 73.71% ± 1.5% inhibition of COX-2 activity, 73.9% ± 0.4% inhibition of protein denaturation, and 75.5% ± 0.83% HRBC membrane stabilisation at maximum concentrations.</div></div><div><h3>Conclusions</h3><div><em>M parvifolia</em> exhibits significant anti-inflammatory properties through modulation of key pathways and targets, combined with strong experimental validation of its efficacy and safety. These findings position <em>M parvifolia</em> as a promising candidate for developing natural, safer anti-inflammatory therapies.</div></div>","PeriodicalId":56077,"journal":{"name":"Journal of Herbal Medicine","volume":"52 ","pages":"Article 101038"},"PeriodicalIF":2.2,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144694492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-01Epub Date: 2025-03-01DOI: 10.1016/j.hermed.2025.101005
Naser Jafari , Fatemeh Hosseini Oskouie , Azadeh Dehghani , Amirhosein Rad , Seyedeh Nooshan Mirmohammadali , Mohammad Javad Alaeian , Farimah Behmanesh Nia , Omid Asbaghi , Ali Hosseini , Moslem Naderian , Mohammad Ali Goudarzi , Ali Zamanian
Introduction
Several research showed that purslane consumption could improve anthropometric indices and blood pressure in the general adult population. Our aim was to conduct a meta-analysis to evaluate the effects of purslane consumption (seed, seed powder, or leaf extract) on body weight (BW), body mass index (BMI), waist circumference, systolic, and diastolic blood pressure due to the contradictory results obtained from prior studies.
Methods
Randomised controlled trial (RCTs) examining the effect of purslane consumption on anthropometric indices and blood pressure in adults were retrieved using online database searches including PubMed, Scopus, and Web of Science up to January 2025. Meta-analysis was carried out using a random-effects model. I2 index was used to evaluate the heterogeneity of RCTs.
Results
Among the initial 611 studies that were identified from electronic databases search, 7 RCTs involving 425 participants were included for data analyses. The results demonstrated that purslane consumption significantly decreased BW ( P < 0.001), BMI (P = 0.017), and systolic blood pressure (P = 0.002); however, purslane consumption did not affect waist circumference (P = 0.249), and diastolic blood pressure (P = 0.697).
Conclusions
This meta-analysis study suggests that purslane consumption may significantly decrease BW and BMI; in addition, it had beneficial effects on systolic blood pressure in adults.
{"title":"The Effects of Purslane Consumption on Blood Pressure and Anthropometric Indices: A Systematic Review and Meta-analysis","authors":"Naser Jafari , Fatemeh Hosseini Oskouie , Azadeh Dehghani , Amirhosein Rad , Seyedeh Nooshan Mirmohammadali , Mohammad Javad Alaeian , Farimah Behmanesh Nia , Omid Asbaghi , Ali Hosseini , Moslem Naderian , Mohammad Ali Goudarzi , Ali Zamanian","doi":"10.1016/j.hermed.2025.101005","DOIUrl":"10.1016/j.hermed.2025.101005","url":null,"abstract":"<div><h3>Introduction</h3><div>Several research showed that purslane consumption could improve anthropometric indices and blood pressure in the general adult population. Our aim was to conduct a meta-analysis to evaluate the effects of purslane consumption (seed, seed powder, or leaf extract) on body weight (<strong>BW</strong>), body mass index (<strong>BMI</strong>), waist circumference, systolic, and diastolic blood pressure due to the contradictory results obtained from prior studies.</div></div><div><h3>Methods</h3><div>Randomised controlled trial (<strong>RCTs</strong>) examining the effect of purslane consumption on anthropometric indices and blood pressure in adults were retrieved using online database searches including PubMed, Scopus, and Web of Science up to January 2025. Meta-analysis was carried out using a random-effects model. I<sup>2</sup> index was used to evaluate the heterogeneity of RCTs.</div></div><div><h3>Results</h3><div>Among the initial 611 studies that were identified from electronic databases search, 7 RCTs involving 425 participants were included for data analyses. The results demonstrated that purslane consumption significantly decreased BW ( <em>P</em> < 0.001), BMI (<em>P</em> = 0.017), and systolic blood pressure (<em>P</em> = 0.002); however, purslane consumption did not affect waist circumference (<em>P</em> = 0.249), and diastolic blood pressure (<em>P</em> = 0.697).</div></div><div><h3>Conclusions</h3><div>This meta-analysis study suggests that purslane consumption may significantly decrease BW and BMI; in addition, it had beneficial effects on systolic blood pressure in adults.</div></div>","PeriodicalId":56077,"journal":{"name":"Journal of Herbal Medicine","volume":"52 ","pages":"Article 101005"},"PeriodicalIF":2.2,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144261378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-01Epub Date: 2025-06-09DOI: 10.1016/j.hermed.2025.101036
Majid Sharifi-Rad , Jibanjyoti Panda , Yugal Kishore Mohanta , Pawel Pohl , Gokhan Zengin , Mark G. Moloney
Introduction
Plant based natural products are well known for their therapeutic potential as they are used to treat many diseases, but these plants need to be validated through the scientific study. Therefore, the present investigation was carried out to evaluate the usefulness of the bioactive compounds present in the essential oils of the Cleome coluteoides.
Methods
Different parts of the plant, including leaves, flowers, fruits, stems and roots, were used to extract the essential oils. The chemical composition of essential oils was analysed by gas-chromatography mass spectrometry (GC-MS). Their antimicrobial properties were evaluated against several human pathogens (three fungi and four bacteria). The enzyme inhibition activity (α-amylase, tyrosinase, butyrylcholinesterase, acetylcholinesterase inhibitory tests) of the essential oils was evaluated, along with, their antioxidant activity (DPPH, 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) tests), xanthine oxidase inhibitory activity, antiproliferative activity (against MCF-7 and Hep-G2), anti-arthritic activity (protein denature assay), and anti-inflammatory activity.
Results
Phytol, sclareol, 7-α-hydroxy manool, and piperitone were found to be the main compounds of the studied essential oils. Notable antibacterial, antifungal, enzyme inhibition, antioxidant, xanthine oxidase inhibitory, antiproliferative, anti-arthritic, and inflammatory activities were found form the essential oils. The best activity was found in the case of the essential oils made from leaves.
Discussion/Conclusions
These potential biological activities along with the chemical constitutes present in the essential oils of C. coluteoides can make them potentially utilisable in different biomedical and therapeutic applications in the future. Additionally, the studied plant and their essential oils can serve as a natural remedy for a variety of lifestyle diseases.
{"title":"Essential oil of Cleome coluteoides (Boiss.): phytochemical constituents, antioxidant, antimicrobial, antiproliferative, anti-inflammatory, enzymatic inhibition, and xanthine oxidase inhibitory properties","authors":"Majid Sharifi-Rad , Jibanjyoti Panda , Yugal Kishore Mohanta , Pawel Pohl , Gokhan Zengin , Mark G. Moloney","doi":"10.1016/j.hermed.2025.101036","DOIUrl":"10.1016/j.hermed.2025.101036","url":null,"abstract":"<div><h3>Introduction</h3><div>Plant based natural products are well known for their therapeutic potential as they are used to treat many diseases, but these plants need to be validated through the scientific study. Therefore, the present investigation was carried out to evaluate the usefulness of the bioactive compounds present in the essential oils of the <em>Cleome coluteoides.</em></div></div><div><h3>Methods</h3><div>Different parts of the plant, including leaves, flowers, fruits, stems and roots, were used to extract the essential oils. The chemical composition of essential oils was analysed by gas-chromatography mass spectrometry (GC-MS). Their antimicrobial properties were evaluated against several human pathogens (three fungi and four bacteria). The enzyme inhibition activity (α-amylase, tyrosinase, butyrylcholinesterase, acetylcholinesterase inhibitory tests) of the essential oils was evaluated, along with, their antioxidant activity (DPPH, 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) tests), xanthine oxidase inhibitory activity, antiproliferative activity (against MCF-7 and Hep-G2), anti-arthritic activity (protein denature assay), and anti-inflammatory activity.</div></div><div><h3>Results</h3><div>Phytol, sclareol, 7-α-hydroxy manool, and piperitone were found to be the main compounds of the studied essential oils. Notable antibacterial, antifungal, enzyme inhibition, antioxidant, xanthine oxidase inhibitory, antiproliferative, anti-arthritic, and inflammatory activities were found form the essential oils. The best activity was found in the case of the essential oils made from leaves.</div></div><div><h3>Discussion<em>/</em>Conclusions</h3><div>These potential biological activities along with the chemical constitutes present in the essential oils of <em>C. coluteoides</em> can make them potentially utilisable in different biomedical and therapeutic applications in the future. Additionally, the studied plant and their essential oils can serve as a natural remedy for a variety of lifestyle diseases.</div></div>","PeriodicalId":56077,"journal":{"name":"Journal of Herbal Medicine","volume":"52 ","pages":"Article 101036"},"PeriodicalIF":2.2,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144516973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Dental caries in children remains a significant public health concern, primarily caused by plaque-forming bacteria such as Streptococcus mutans. Effective antimicrobial alternatives from natural sources are increasingly explored to address this issue.
Methods
This study evaluated the antibacterial activity of Piper betel L. (PB) leaf extract against Streptococcus mutans using the agar diffusion method. PB extract was obtained via ethanol maceration and formulated into lozenges with varying binder types and concentrations. The formulations were assessed for inhibition zone diameter and key physical parameters such as tablet uniformity, friability, hardness, and disintegration time.
Results
Piper betel L. extract demonstrated strong antibacterial activity, with the 7.5% concentration yielding an inhibition zone of 22.76 mm, comparable to that of 10%. Lozenges containing 7.5% PB extract exhibited acceptable physicochemical properties across all formulations, with disintegration times under 9 minutes, friability below 0.1%, and tablet hardness ranging from 48.67 to 77.09 N.
Conclusions
Piper betel L. leaf extract formulated as lozenges demonstrates significant antimicrobial potential for preventing dental caries, supported by effective inhibition of Streptococcus mutans and acceptable pharmaceutical properties.
{"title":"Piper betel L. Leaf Extract Lozenges for Preventing Dental Caries for Children","authors":"Desy Nawangsari , Tatiana Siregar , Ikhwan Yuda Kusuma","doi":"10.1016/j.hermed.2025.101032","DOIUrl":"10.1016/j.hermed.2025.101032","url":null,"abstract":"<div><h3>Introduction</h3><div>Dental caries in children remains a significant public health concern, primarily caused by plaque-forming bacteria such as <em>Streptococcus mutans.</em> Effective antimicrobial alternatives from natural sources are increasingly explored to address this issue.</div></div><div><h3>Methods</h3><div>This study evaluated the antibacterial activity of <em>Piper betel L.</em> (<strong>PB</strong>) leaf extract against <em>Streptococcus mutans</em> using the agar diffusion method. PB extract was obtained via ethanol maceration and formulated into lozenges with varying binder types and concentrations. The formulations were assessed for inhibition zone diameter and key physical parameters such as tablet uniformity, friability, hardness, and disintegration time.</div></div><div><h3>Results</h3><div><em>Piper betel L.</em> extract demonstrated strong antibacterial activity, with the 7.5% concentration yielding an inhibition zone of 22.76 mm, comparable to that of 10%. Lozenges containing 7.5% PB extract exhibited acceptable physicochemical properties across all formulations, with disintegration times under 9 minutes, friability below 0.1%, and tablet hardness ranging from 48.67 to 77.09 N.</div></div><div><h3>Conclusions</h3><div><em>Piper betel L.</em> leaf extract formulated as lozenges demonstrates significant antimicrobial potential for preventing dental caries, supported by effective inhibition of <em>Streptococcus mutans</em> and acceptable pharmaceutical properties.</div></div>","PeriodicalId":56077,"journal":{"name":"Journal of Herbal Medicine","volume":"52 ","pages":"Article 101032"},"PeriodicalIF":2.2,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144297204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-01Epub Date: 2025-06-06DOI: 10.1016/j.hermed.2025.101035
Shuvam Sar , Nurul Hassan Mondal , Tanmoy Banerjee , Amit Kumar Halder , Nilanjan Ghosh
Introduction
Tinospora crispa (TC), also known as ‘Petawali,’ is an Indian medicinal plant renowned in folk medicine and Ayurveda for its extensive therapeutic properties. Despite its known benefits, the hepatoprotective potential of TC, particularly against Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), remains unexplored scientifically. This study aims to identify phytocompounds in TC that may be effective against NAFLD/NASH-related targets and elucidate their mechanisms of action.
Method
We utilised fingerprint-based similarity search analyses to predict targets for each phytocompound. Network pharmacology, facilitated by ‘Cytoscape’ and its ‘Cytohubba’ plugins, was employed to establish connections between specific phytocompounds of TC and potential targets of NAFLD. Molecular docking followed by MM/GB(PB)SA scoring analyses were performed with these phytochemicals against a range of crystal structures and homology models of biological target proteins. Around 500 ns molecular dynamics simulations were conducted for the selected biological targets and docked phytoconstituents to understand dynamic behaviours of the complexes.
Result
Molecular docking and MM/GB(PB)SA scoring revealed that 3′-O-methylluteolin, diosmetin, genkwanin, and luteolin may show promising activity whereas molecular dynamics simulation highlighted that 3′-O-methylluteolin might be the most suitable phytochemical for NAFLD treatment.
Conclusion
Overall, these four compounds may modulate key proteins such as CYP3A4, MMP1, PPARδ, PPARγ, AKT1, CYP1A2, and STAT3. This study provides a scientific basis for the potential use of TC in managing NAFLD and NASH, encouraging further research and development in this domain.
tinospora crispa (TC),也被称为“Petawali”,是一种印度药用植物,因其广泛的治疗特性而在民间医学和阿育吠陀中享有盛誉。尽管有已知的益处,但TC的肝保护潜力,特别是对非酒精性脂肪性肝病(NAFLD)和非酒精性脂肪性肝炎(NASH)的保护潜力仍未得到科学探索。本研究旨在鉴定TC中可能对NAFLD/ nash相关靶点有效的植物化合物,并阐明其作用机制。方法采用基于指纹图谱的相似度搜索分析方法预测各植物化合物的靶点。网络药理学,通过‘ Cytoscape ’及其‘ Cytohubba ’插件,建立了TC特定植物化合物与NAFLD潜在靶点之间的联系。对这些植物化学物质进行分子对接,然后进行MM/GB(PB)SA评分分析,与一系列生物靶蛋白的晶体结构和同源性模型进行比较。对选定的生物靶点和对接的植物成分进行了约500 ns的分子动力学模拟,以了解配合物的动力学行为。结果分子对接和MM/GB(PB)SA评分显示,3′- o -甲基木犀草素、洋芋素、根宽素和木犀草素可能具有良好的活性,而分子动力学模拟显示,3′- o -甲基木犀草素可能是治疗NAFLD最合适的植物化学物质。综上所述,这4种化合物可能调控CYP3A4、MMP1、PPARδ、PPARγ、AKT1、CYP1A2和STAT3等关键蛋白。本研究为TC在NAFLD和NASH治疗中的潜在应用提供了科学依据,鼓励了该领域的进一步研究和发展。
{"title":"Targeting NAFLD and NASH with Tinospora crispa: insights from network pharmacology and molecular dynamics","authors":"Shuvam Sar , Nurul Hassan Mondal , Tanmoy Banerjee , Amit Kumar Halder , Nilanjan Ghosh","doi":"10.1016/j.hermed.2025.101035","DOIUrl":"10.1016/j.hermed.2025.101035","url":null,"abstract":"<div><h3>Introduction</h3><div><em>Tinospora crispa</em> (TC), also known as ‘Petawali,’ is an Indian medicinal plant renowned in folk medicine and Ayurveda for its extensive therapeutic properties. Despite its known benefits, the hepatoprotective potential of TC, particularly against Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), remains unexplored scientifically. This study aims to identify phytocompounds in TC that may be effective against NAFLD/NASH-related targets and elucidate their mechanisms of action.</div></div><div><h3>Method</h3><div>We utilised fingerprint-based similarity search analyses to predict targets for each phytocompound. Network pharmacology, facilitated by ‘Cytoscape’ and its ‘Cytohubba’ plugins, was employed to establish connections between specific phytocompounds of TC and potential targets of NAFLD. Molecular docking followed by MM/GB(PB)SA scoring analyses were performed with these phytochemicals against a range of crystal structures and homology models of biological target proteins. Around 500 ns molecular dynamics simulations were conducted for the selected biological targets and docked phytoconstituents to understand dynamic behaviours of the complexes.</div></div><div><h3>Result</h3><div>Molecular docking and MM/GB(PB)SA scoring revealed that 3′-O-methylluteolin, diosmetin, genkwanin, and luteolin may show promising activity whereas molecular dynamics simulation highlighted that 3′-O-methylluteolin might be the most suitable phytochemical for NAFLD treatment.</div></div><div><h3>Conclusion</h3><div>Overall, these four compounds may modulate key proteins such as CYP3A4, MMP1, PPARδ, PPARγ, AKT1, CYP1A2, and STAT3. This study provides a scientific basis for the potential use of TC in managing NAFLD and NASH, encouraging further research and development in this domain.</div></div>","PeriodicalId":56077,"journal":{"name":"Journal of Herbal Medicine","volume":"52 ","pages":"Article 101035"},"PeriodicalIF":2.2,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144580577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}